Table 1.
Characteristics of subjects in the 2 groups
| TA Group, n = 46 | NTA Group,n = 109 | P Value | |
|---|---|---|---|
| Mean age, y | 54.1 ± 8.9 | 55.4 ± 10.8 | NS |
| Female sex | 43 (96) | 100 (93) | NS |
| BMI, kg/m2 | 30 ± 7.2 | 28.6 ± 7.7 | NS |
| Non‐Caucasian race | 17 (37) | 31 (28) | NS |
| Current smoking | 1 (2.2) | 1 (0.9) | NS |
| History of HTN | 29 (63) | 55 (51) | NS |
| History of DM | 8 (17) | 18 (17) | NS |
| History of hyperlipidemia | 26 (56) | 55 (51) | NS |
| Family history of premature CAD | 30 (65) | 67 (64) | NS |
| Postmenopausal | 37 (86) | 80 (80) | NS |
| Prior MI | 3 (7) | 8 (8) | NS |
| Associated symptoms | |||
| Shortness of breath | 37 (80) | 63 (60) | 0.016 |
| Palpitations | 22 (48) | 43 (41) | NS |
| Nausea | 17 (37) | 30 (29) | NS |
| Medications | |||
| β‐Blockers | 17 (37) | 46 (44) | NS |
| CCBs | 15 (33) | 22 (21) | NS |
| ACEIs | 12 (26) | 17 (16) | NS |
| ARBs | 6 (13) | 11 (11) | NS |
| Nitrates | 25 (54) | 33 (31) | 0.011 |
| Statins | 22 (48) | 61 (58) | NS |
| HRT | 6 (14) | 13 (13) | NS |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; DM, diabetes mellitus; HRT, hormone replacement therapy; HTN, hypertension; MI, myocardial infarction; NS, not significant; NTA, nontypical angina; SD, standard deviation; TA, typical angina.
Data are presented as n (%) or mean ± SD.